Advanced in Eosinophilic Fasciitis

Dr. Suzanne Kafaja

Rheumatology
The Regents Of The University Of California
900 Weyburn Place, Suite 14 171, 
Los Angeles, CA 
Offers Telehealth
Advanced in Eosinophilic Fasciitis
The Regents Of The University Of California
900 Weyburn Place, Suite 14 171, 
Los Angeles, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Suzanne Kafaja is a Rheumatologist in Los Angeles, California. Dr. Kafaja is rated as an Advanced provider by MediFind in the treatment of Eosinophilic Fasciitis. Her top areas of expertise are Scleroderma, Systemic Sclerosis (SSc), Scleroma, and Localized Scleroderma.

Her clinical research consists of co-authoring 34 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Rheumatology
Licenses
Internal Medicine in CA
Hospital Affiliations
Ronald Reagan UCLA Medical Center
Santa Monica - UCLA Med Ctr & Orthopaedic Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

HMSA
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
LA Care
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
SCAN Health Plan
  • INSURANCE PLAN
  • MEDICARE MAPD
Silversummit Health Plan
  • HMO
  • MANAGED MEDICAID PLAN
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 13 Less Insurance Carriers -

Locations

THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
900 Weyburn Place, Suite 14 171, Los Angeles, CA 90095
Other Locations
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
2020 Santa Monica Blvd, Suite 210, Santa Monica, CA 90404
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
200 Ucla Medical Plz, Suite 165 34, Los Angeles, CA 90095

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Phase 2 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Ifetroban in Patients With Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension (SSc-PAH)
A Phase 2 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Ifetroban in Patients With Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension (SSc-PAH)
Enrollment Status: Active_not_recruiting
Publish Date: July 10, 2025
Intervention Type: Drug
Study Drug: Ifetroban
Study Phase: Phase 2
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 3 Study Evaluating the Safety and Efficacy of Intravenous Iloprost in Subjects With Systemic Sclerosis Experiencing Symptomatic Digital Ischemic Episodes (AURORA Study)
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 3 Study Evaluating the Safety and Efficacy of Intravenous Iloprost in Subjects With Systemic Sclerosis Experiencing Symptomatic Digital Ischemic Episodes (AURORA Study)
Enrollment Status: Completed
Publish Date: May 25, 2025
Intervention Type: Drug
Study Drug: Iloprost
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Repeat-Dose, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics, and Explore Efficacy of TEPEZZA in Patients With Diffuse Cutaneous Systemic Sclerosis
A Randomized, Double-Blind, Placebo-Controlled, Repeat-Dose, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics, and Explore Efficacy of TEPEZZA in Patients With Diffuse Cutaneous Systemic Sclerosis
Enrollment Status: Terminated
Publish Date: June 28, 2024
Intervention Type: Biological, Other
Study Drug: Tepezza Anti-IGF-1 Receptor Monoclonal Antibody
Study Phase: Phase 1
Evaluation of Brentuximab Vedotin for Diffuse Cutaneous Systemic Sclerosis BRAVOS: A Phase 1/2 Multicenter Randomized, Double Blinded, Safety Study (ITN075AI)
Evaluation of Brentuximab Vedotin for Diffuse Cutaneous Systemic Sclerosis BRAVOS: A Phase 1/2 Multicenter Randomized, Double Blinded, Safety Study (ITN075AI)
Enrollment Status: Completed
Publish Date: May 17, 2024
Intervention Type: Biological
Study Drug: Brentuximab vedotin
Study Phase: Phase 1/Phase 2
A Phase 2, Randomized, Placebo-controlled, Double-blind, Open-label Extension Multicenter Study to Evaluate the Efficacy and Safety of Belumosudil (KD025) in Subjects With Diffuse Cutaneous Systemic Sclerosis
A Phase 2, Randomized, Placebo-controlled, Double-blind, Open-label Extension Multicenter Study to Evaluate the Efficacy and Safety of Belumosudil (KD025) in Subjects With Diffuse Cutaneous Systemic Sclerosis
Enrollment Status: Terminated
Publish Date: August 30, 2023
Intervention Type: Drug
Study Drug: Belumosudil (KD025)
Study Phase: Phase 2
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis
Enrollment Status: Terminated
Publish Date: March 29, 2021
Intervention Type: Drug, Other
Study Phase: Phase 3
A Phase 2 Study to Evaluate Subcutaneous Abatacept vs. Placebo in Diffuse Cutaneous Systemic Sclerosis- a Double-blind, Placebo-controlled, Randomized Controlled Trial.
A Phase 2 Study to Evaluate Subcutaneous Abatacept vs. Placebo in Diffuse Cutaneous Systemic Sclerosis- a Double-blind, Placebo-controlled, Randomized Controlled Trial.
Enrollment Status: Completed
Publish Date: February 17, 2020
Intervention Type: Drug
Study Phase: Phase 2
View 6 Less Clinical Trials

34 Total Publications

Comparative Efficacy of Immunosuppressive Therapies in the Treatment of Diffuse Cutaneous Systemic Sclerosis.
Comparative Efficacy of Immunosuppressive Therapies in the Treatment of Diffuse Cutaneous Systemic Sclerosis.
Journal: ACR open rheumatology
Published: November 13, 2024
Similar Doctors
Distinguished in Eosinophilic Fasciitis
Dr. Stratos C. Christianakis
Rheumatology
Distinguished in Eosinophilic Fasciitis
Dr. Stratos C. Christianakis
Rheumatology

USC Care Medical Group Inc

1450 San Pablo St, 
Los Angeles, CA 
 (14.2 miles away)
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Stratos Christianakis is a Rheumatologist in Los Angeles, California. Dr. Christianakis is rated as a Distinguished provider by MediFind in the treatment of Eosinophilic Fasciitis. His top areas of expertise are Scleroma, Systemic Sclerosis (SSc), Rheumatoid Arthritis (RA), and Scleroderma.

Advanced in Eosinophilic Fasciitis
Dr. Rachel P. Mory
Rheumatology
Advanced in Eosinophilic Fasciitis
Dr. Rachel P. Mory
Rheumatology

County Of Ventura

300 Hillmont Ave, 
Ventura, CA 
 (48.2 miles away)
Languages Spoken:
English
See accepted insurances

Rachel Mory is a Rheumatologist in Ventura, California. Dr. Mory is rated as an Advanced provider by MediFind in the treatment of Eosinophilic Fasciitis. Her top areas of expertise are Eosinophilic Fasciitis, Rheumatoid Arthritis (RA), Microscopic Polyangiitis, and Relapsing Polychondritis.

Advanced in Eosinophilic Fasciitis
Dr. Martin M. Weiss
Rheumatology
Advanced in Eosinophilic Fasciitis
Dr. Martin M. Weiss
Rheumatology
16111 Plummer St, 
North Hills, CA 
 (12.7 miles away)
818-891-7711
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Martin Weiss is a Rheumatologist in North Hills, California. Dr. Weiss is rated as an Advanced provider by MediFind in the treatment of Eosinophilic Fasciitis. His top areas of expertise are Rheumatoid Arthritis (RA), Fibromyalgia, Microscopic Polyangiitis, and Scleroma. Dr. Weiss is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Kafaja's expertise for a condition
ConditionClose
View All 24 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile